Financial toxicity and time toxicity in multiple myeloma: Prevalence, predictors, and impact on QOL

Patients with multiple myeloma can experience an ongoing risk of financial toxicity from medication costs and lost productivity, as well as time toxicity, given the ongoing monitoring and supportive care required. More than 250 patients were surveyed about financial stressors, frequency/convenience of in-person vs. telehealth visits, and physical/mental quality of life to assess the impact of these toxicities on quality of life. Results suggest patients benefit from financial toxicity screening and early referral to financial navigation services. With time toxicity reported by more than a third of patients, further research into reversible drivers of this toxicity is needed.